Biology Insights

What Does a Positive QuantiFERON Gold Test Mean?

Understand what a positive QuantiFERON Gold test signifies for your health and the necessary next steps for diagnosis and ongoing care.

By Alexander Lindstrom

A positive QuantiFERON Gold test means your immune system has been exposed to the bacteria that cause tuberculosis. It does not mean you are sick with TB or that you are contagious. In most cases, it points to latent TB infection, where the bacteria are present in your body but dormant and not causing symptoms. The distinction between latent infection and active disease is critical, and a positive QuantiFERON result is just the first step in figuring out what comes next.

What the Test Measures

The QuantiFERON-TB Gold test is a blood test that detects whether your immune cells have learned to recognize specific proteins found on Mycobacterium tuberculosis, the bacterium that causes TB. When blood is drawn and mixed with those proteins in a tube, immune cells that have previously encountered TB will release a signaling molecule called interferon-gamma. The lab measures how much interferon-gamma is produced. If it exceeds a set threshold (0.35 IU/mL above the background level), the result is reported as positive.

The proteins used in the test, called ESAT-6 and CFP-10, are found almost exclusively in M. tuberculosis and a handful of closely related species. They are not present in the BCG vaccine strain used in many countries. This is a major advantage over the older tuberculin skin test, which often gives a false positive in people who received the BCG vaccine as children. In one study comparing BCG-vaccinated patients, those with positive QuantiFERON results had meaningfully different clinical profiles than those who were merely skin-test positive, supporting the idea that the blood test better identifies true infection rather than vaccine-related immune memory.

Latent Infection Versus Active Disease

The most important thing to understand about a positive result is that it cannot, by itself, tell you whether your TB infection is latent or active. Roughly a quarter of the world’s population carries latent TB, yet the vast majority of those people will never get sick. A positive QuantiFERON result puts you in that broad group. To rule out active TB, your doctor will typically order a chest X-ray and ask about symptoms like a persistent cough, fever, night sweats, or unexplained weight loss. If the X-ray is normal and you have no symptoms, the working diagnosis is latent TB infection.

The risk of a latent infection progressing to active disease is generally estimated at around 5 to 10 percent over a lifetime in otherwise healthy people. A study of immigrant close contacts of active TB patients found that about 3 percent of those who tested positive on the QuantiFERON developed active TB during a follow-up period, which was comparable to the rate seen with the older skin test. In other words, a positive test raises a flag but the actual chance of getting sick remains relatively low for most people.

When a Positive Might Not Mean True Infection

No diagnostic test is perfect, and false positives do happen. One concern is cross-reactivity with nontuberculous mycobacteria (NTM), a group of environmental organisms that can sometimes cause lung infections. A study in Northern California found that the QuantiFERON’s specificity in patients with confirmed NTM infection was about 76 percent overall. However, once patients who also had risk factors for actual TB exposure were excluded, the specificity jumped to about 94 percent. That study also found only two patients with NTM species known to cross-react with the test antigens, suggesting this is an uncommon problem in practice.

The bigger false-positive concern arises in serial testing of low-risk populations such as healthcare workers in countries where TB is uncommon. A modeling study projected that after ten years of annual QuantiFERON screening, about 25 percent of tested individuals would have received at least one false-positive result, compared to less than 1 percent true positives. That works out to roughly 29 false positives for every genuine new infection detected. This has driven many healthcare systems to reconsider routine annual testing in low-risk workers and instead focus testing on people with actual TB exposure.

Borderline Results and the Grey Zone

The cutoff for a positive QuantiFERON is 0.35 IU/mL, but biology does not produce sharp dividing lines. Results that fall close to this threshold, in either direction, tend to be unreliable. A retrospective analysis of patients with initial borderline results found striking instability: among those initially classified as borderline positive, nearly three-quarters reverted to negative or borderline negative on repeat testing. Among those initially borderline negative, about 17 percent flipped to positive or borderline positive.

Researchers have proposed an “equivocal zone” around the cutoff to flag these uncertain results. One analysis found that nearly one-fifth of results just below 0.35 IU/mL were positive when repeated, and half of those just above the threshold were negative on retesting. If your QuantiFERON comes back positive but the interferon-gamma value is only slightly above the cutoff, your doctor may recommend repeating the test before committing to treatment. This grey zone is an area where the science is still catching up to clinical practice, and variability from follow-up testing is well documented.

Indeterminate Results Are Something Else Entirely

An indeterminate QuantiFERON result is not a “weak positive” or a “borderline negative.” It means the test itself failed to work properly, usually because the positive control tube did not produce an adequate immune response. In about 96 percent of indeterminate cases in one large study, the problem was traced to a low response to the mitogen control, meaning the patient’s immune cells simply did not react strongly enough for the test to generate any interpretable result.

Several patient-related and laboratory-related factors increase the likelihood of an indeterminate result:

If you receive an indeterminate result, it typically means the test should be repeated, ideally after any acute illness resolves. It tells you nothing about whether you have TB.

How the Test Performs in People with Weakened Immune Systems

One of the tricky situations in TB testing is when the patient’s immune system is suppressed, whether by HIV, organ transplant medications, chemotherapy, or drugs for autoimmune conditions. A weakened immune system might not mount a strong enough interferon-gamma response to produce a positive result even when TB bacteria are genuinely present. A large prospective study found that the QuantiFERON’s sensitivity dropped from about 81 percent in people with healthy immune systems to 70 percent in immunocompromised individuals.

The implications vary depending on the type of immunosuppression. In that same study, among patients with chronic kidney failure, rheumatoid arthritis, or organ transplants who had positive QuantiFERON results but did not receive preventive TB treatment, none developed active TB over more than 2,400 person-years of follow-up. Among people living with HIV who had positive results and did not receive preventive treatment, however, the picture was starkly different: the incidence of active TB was about 4 per 100 person-years, and those who progressed all had uncontrolled HIV with low CD4 counts. Research into the newer QuantiFERON-Plus version found that its sensitivity held up well in HIV-positive patients with active TB, though it also revealed that HIV impairs the specific type of immune-cell response the test relies on.

A separate analysis of patients with chronic inflammatory diseases found positive rates of about 15 to 28 percent depending on the condition, with psoriasis patients showing the highest positivity. None of those positive patients developed active TB over four years of follow-up. For clinicians, the takeaway is that a positive QuantiFERON in someone on immunosuppressive therapy still warrants evaluation, but the urgency of preventive treatment depends heavily on the specific type and degree of immunosuppression.

Positive Results in Children

There has been longstanding uncertainty about how well the QuantiFERON performs in very young children, whose immune systems are still developing. A multicenter study put some of that concern to rest, finding that the test’s sensitivity in children under two years old was about 94 percent, actually higher than the roughly 81 percent seen in adults with culture-confirmed TB. The rate of indeterminate results was also lower in children at about 2 percent compared to 5 percent in adults. A smaller study of children under 36 months similarly found no false negatives among those with confirmed active TB, with a specificity of 100 percent.

This matters because many countries vaccinate children with BCG at birth, making the skin test unreliable in pediatric populations. A positive QuantiFERON in a child, especially one who is a close contact of an adult with active TB, carries real clinical weight and typically leads to a chest X-ray and consideration of preventive treatment. Cost-effectiveness analyses in settings with universal BCG vaccination have found the QuantiFERON to be cost-effective for diagnosing latent TB in children compared to the skin test alone.

Results That Flip on Repeat Testing

If you have been tested more than once, you may have seen your result change from positive to negative or vice versa. These conversions and reversions happen more often than most people realize. In a study of U.S. healthcare workers, 45 percent of those with an initial positive QuantiFERON reverted to negative on repeat testing a year later. Among workers whose tests converted from negative to positive, 90 percent reverted back to negative on a third test. The authors of that study concluded that current interpretation criteria make the QuantiFERON a poor choice for routine serial screening in low-risk populations.

What predicts whether a positive result will stick? The strength of the initial result matters enormously. In a study of healthcare workers in an intermediate-burden country, those with high baseline interferon-gamma values (above roughly 0.74 IU/mL) were far less likely to revert. Among those who did revert, 78 percent had started with values below that threshold. A cohort study of South African adolescents found that reversion was strongly associated with lower initial values, and also that even people who reverted had elevated TB risk compared to those who always tested negative, with about eight times the incidence of active TB. That last finding is sobering: a result that bounces from positive to negative may not mean the infection has cleared.

A Positive Test Stays Positive After Treatment

One common expectation after completing treatment for latent TB is that the QuantiFERON should turn negative. It usually does not. Studies have consistently shown that most people remain positive even after a full course of preventive therapy. In one study, about 88 percent of patients were still QuantiFERON-positive three months after finishing treatment, and about 85 percent remained positive at 15 months. The average interferon-gamma levels barely budged.

This means the test should not be used to monitor whether treatment worked. Researchers have been explicit on this point: interferon-gamma responses do not reliably change after nine months of isoniazid or other preventive regimens, and neither patients nor doctors should expect them to. If you completed treatment years ago and get tested again for a new job or immigration requirement, a positive result does not mean the treatment failed. It simply reflects a lasting immune memory of the original exposure.

What Happens After You Get a Positive Result

The immediate next steps after a positive QuantiFERON typically include a chest X-ray to check for signs of active TB disease and a clinical evaluation for symptoms. If the X-ray is clear and you are symptom-free, the diagnosis is latent TB infection, and your doctor will discuss whether preventive treatment makes sense for you. The decision depends on several factors: how recently you were exposed, whether you are about to start immunosuppressive therapy, your age, and your overall risk profile.

Treatment options for latent TB have expanded beyond the traditional nine-month course of isoniazid. A shorter regimen combining rifapentine and isoniazid given once weekly for three months has become widely adopted and is generally better tolerated. Other options include four months of rifampin alone. The goal of all these regimens is the same: to kill dormant bacteria before they have a chance to reactivate, especially if your immune system weakens later in life.

Pre-Analytical Factors That Can Skew Your Result

The QuantiFERON is a demanding test from a laboratory standpoint, and how the blood sample is handled before it reaches the analyzer can meaningfully affect the result. The blood must be collected into specific tubes, shaken to mix it with the antigens, and incubated within a set time window. Delays in incubation are a well-documented problem. One study found that waiting just six hours before incubating the sample caused about 19 percent of positive results to flip to negative, and a 12-hour delay caused a 22 percent reversion rate.

Other common handling errors include drawing too much or too little blood into the collection tubes, mixing up the tubes, and storing samples at the wrong temperature before incubation. Even who draws the blood can matter: one hospital study found that samples collected by non-phlebotomists were three times more likely to yield indeterminate results than those drawn by trained phlebotomists. If your result seems inconsistent with your clinical picture, these pre-analytical variables are worth considering before assuming the biology does not add up.

Cost and Screening Strategy Depend on the Setting

Whether the QuantiFERON is the right test to use depends heavily on where you live and your risk profile. In countries with widespread BCG vaccination, the QuantiFERON avoids the false positives that plague the skin test and has been shown to be cost-effective for diagnosing latent TB in children. But in high-burden settings where TB prevalence is high and the skin test performs well enough, the economics can favor the much cheaper skin test. An analysis from Brazil found that the skin test alone was the most cost-effective strategy for screening TB contacts, and that the QuantiFERON only became competitive if its price dropped substantially. A separate Brazilian analysis of healthcare workers reached a similar conclusion.

In practice, many guidelines now recommend the QuantiFERON (or a two-step strategy using the skin test first and confirming positives with the blood test) for BCG-vaccinated individuals, immunocompromised patients, and people in low-burden countries where the positive predictive value of the skin test is poor. If you are being tested for employment or immigration in a low-prevalence country, you are in one of the situations where the QuantiFERON’s higher specificity matters most, because a false positive from the skin test could lead to unnecessary treatment. Conversely, if you live in a high-prevalence area and were recently exposed to someone with active TB, either test will give your doctor useful information, and cost may tip the scale toward the skin test.

Related Content

More in Tests